GlassScriptPhysician profile
Benny G Chu
NPI 1851483754
$2,637.22
in general payments reported to CMS, 2019-2025
32 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $141 · 2021: $147 · 2022: $538 · 2023: $530 · 2024: $237 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $536.06 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $292.43 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $253.94 | 2019-2025 | Lagevrio, Verquvo |
| Exact Sciences Corporation | $193.73 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $186.60 | 2019-2022 | |
| Pfizer INC. | $131.71 | 2019-2023 | |
| Amarin Pharma, INC. | $131.46 | 2019-2022 | |
| Abbvie INC. | $128.86 | 2019-2025 | Vraylar |
| Kowa Pharmaceuticals America, INC. | $101.94 | 2019-2025 | Zoryve |
| Amgen INC. | $87.84 | 2019-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $70.45 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $59.88 | 2022-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $44.20 | 2023 | Quviviq |
| Lilly USA, LLC | $43.29 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.19 | 2020-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $34.37 | 2025 | |
| Seqirus USA INC | $34.00 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Eisai INC. | $29.67 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $28.85 | 2019 | |
| Boston Scientific Corporation | $23.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.40 | 2025 | |
| Azurity Pharmaceuticals, INC. | $17.79 | 2025 | Edarbi |
| Bayer Healthcare Pharmaceuticals INC. | $15.94 | 2021 | |
| Currax Pharmaceuticals LLC | $15.63 | 2023 | Contrave |
| Sanofi Pasteur INC. | $15.12 | 2023 | |
| Biotronik Nro, INC. | $14.75 | 2025 | Prospera |
| Alexion Pharmaceuticals, INC. | $14.60 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2023 | Eliquis |
| Genentech USA, INC. | $13.85 | 2019 | |
| Esperion Therapeutics, INC. | $13.75 | 2022 | |
| Hikma Pharmaceuticals USA | $13.32 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benny Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.